Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer

Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer

Thyroid cancer is the most common (~90%) type of endocrine-system tumor, accounting for 70% of the deaths from endocrine cancers. In the last years, the high-throughput genomics has been able to identify pathways/molecular targets involved in survival and tumor progression. Targeted therapy and immu...

Full description

Bibliographic Details
Main Authors: Francesca Ragusa, Silvia Martina Ferrari, Giusy Elia, Sabrina Rosaria Paparo, Eugenia Balestri, Chiara Botrini, Armando Patrizio, Valeria Mazzi, Giovanni Guglielmi, Rudy Foddis, Claudio Spinelli, Salvatore Ulisse, Alessandro Antonelli, Poupak Fallahi
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:International Journal of Molecular Sciences
Subjects:
thyroid cancer
immunotherapy
new checkpoint inhibitors
tyrosine kinase inhibitors
PD-1 inhibitors
PD-L1 inhibitors
Online Access:https://www.mdpi.com/1422-0067/23/10/5731

Internet

https://www.mdpi.com/1422-0067/23/10/5731

Similar Items